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ABSTRACT 
 
 
The aim of this study is to evaluate the prophylactic anti-emetic effect of 
intravenous dexamethasone in post operative nausea and vomiting.  
The following were found to increase the incidence of PONV: Female 
gender, history of PONV, history of motion sickness, post operative pain 
and type of operation mainly laproscopic surgery. 
One hundred fifty patients requiring general anesthesia for different 
types of operations were enrolled in a randomized, double blind, 
placebo-controlled study. 
Fifty patients received dexamethasone 6mg intravenously group (A), 50 
patients received dexamethasone 10mg i.v group (B) and 50 patients 
taken as control group received normal saline 2ml i.v group (C) at the 
induction of anesthesia. 
We found that, the comparison between the three groups showed:  
Group (A) 22%  of patient had Nausea, 12% of patient had vomiting. 
Group (B) 16% of patient had Nausea, 12% of patient had vomiting. 
Group (C) 76% of patient  had Nausea, 44% of patient had vomiting. 
The study clearly showed that dexamethasone 10mg and 6mg 
significantly decreased the incidence of postoperative vomiting, while 
dexamethasone 10mg was more effective in reducing the incidence of 
post operative nausea. 
 IV
 
 ﻣﻠﺨﺺ ﺍﻷﻃﺮﻭﺣﺔ
  
ﺤﺩﻴﺩ ﺍﻟﺩﻭﺭ ﺍﻟﻭﻗﺎﺌﻲ ﻟﻌﻘﺎﺭ ﺍﻟﺩﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ ﻓـﻲ ﺤـﺩﻭﺙ ﺘﻬﺩﻑ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺇﻟﻰ ﺘ
ﺍﻟﻐﺜﻴﺎﻥ ﻭﺍﻟﺘﻘﻴﺅ ﺒﻌﺩ ﺇﺠﺭﺍﺀ ﺍﻟﻌﻤﻠﻴﺎﺕ ﺒﺄﻨﻭﺍﻋﻬﺎ ﺍﻟﻤﺨﺘﻠﻔﺔ، ﺃﻴﻀﺎﹰ ﺍﻟﻌﻭﺍﻤل ﺍﻟﺨﻁﺭﺓ ﺍﻟﺘﻲ ﺘﺅﺩﻱ 
  -:ﺇﻟﻰ ﺍﻟﻐﺜﻴﺎﻥ ﻭﺍﻟﺘﻘﻴﺅ ﺒﻌﺩ ﺍﻟﻌﻤﻠﻴﺎﺕ ﻭﻜﺎﻨﺕ ﻜﺎﻵﺘﻲ
ﺜﻡ ﺍﻟﺠﻨﺱ ﺍﻷﻨﺜﻭﻱ، ﺍﻟﻼﺘﻲ ﻴﻌﻨﻴﻥ ﺍﻟﻐﺜﻴﺎﻥ ﻭﺍﻟﺘﻘﻴﺅ ﻭﺩﻭﺍﺭ ﺍﻟﺤﺭﻜﺔ، ﺍﻷﻟﻡ ﺒﻌﺩ ﺍﻟﻌﻤﻠﻴﺔ 
  .ﻨﻭﻉ ﺍﻟﻌﻤﻠﻴﺔ ﻭﻜﺎﻨﺕ ﺃﻫﻤﻬﺎ ﻋﻤﻠﻴﺎﺕ ﺍﻟﻤﻨﺎﻅﻴﺭ
ﻤﺭﻴﺽ  051ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ ﻭﺍﻟﺘﺠﺭﺒﺔ ﺍﻟﻤﺤﺠﻭﺒﺔ ﺍﻟﻤﺯﺩﻭﺠﺔ ﻋﻠﻰ 
ﺍﻟﺠﺭﺍﺤﻴﺔ ﺍﻟﻤﺨﺘﻠﻔﺔ ﻭﻜﺎﻨﺕ  ﻤﺒﺎﺸﺭﺓ ﺒﻌﺩ ﺍﻟﺘﺨﺩﻴﺭ ﺍﻟﻘﻴﺎﺴﻲ ﺍﻟﻌﺎﻡ ﻹﺠﺭﺍﺀ ﺍﻟﻌﻤﻠﻴﺎﺕ ﺔﻭﻤﺭﻴﻀ
  -:ﻜﺂﻻﺘﻲ
  (.لﻤ2)ﻤﻠﺠﻡ ﺒﺎﻟﻭﺭﻴﺩ ( 6)ﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ ﺩ( ﺃ)ﻤﺭﻴﺽ ﺍﻟﻤﺠﻤﻭﻋﺔ  05 ?
  (.ﻤل2)ﻤﻠﺠﻡ ﺒﺎﻟﻭﺭﻴﺩ ( 01)ﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ ( ﺏ)ﻤﺭﻴﺽ ﺍﻟﻤﺠﻤﻭﻋﺔ  05 ?
  (. ﻤل2)ﻤﻠﺢ ﻁﻌﺎﻡ ﺒﺎﻟﻭﺭﻴﺩ % 9,0ﻋﻼﺝ ﺍﺭﻀﺎﺌﻲ( ﺝ)ﻤﺭﻴﺽ ﺍﻟﻤﺠﻤﻭﻋﺔ  05 ?
ﻭﺒﺎﻟﻤﻘﺎﺭﻨـﺔ ﺒـﻴﻥ % 22ـ ﺜﻡ ﻗﺩﺭ ﺤﺩﻭﺙ ﺍﻟﺘﻘﻴﺅ ﺒ  ـ% 83ـ ﻗﺩﺭ ﺤﺩﻭﺙ ﺍﻟﻐﺜﻴﺎﻥ ﺒ
  ﺍﻟﺜﻼﺙ ﻤﺠﻤﻭﻋﺎﺕ ﻭﺠﺩ ﺃﻥ 
  . ﺘﻘﻴﺅ% 21ﻏﺜﻴﺎﻥ % 22( ﺃ)ﺍﻟﻤﺠﻤﻭﻋﺔ  ?
  . ﺘﻘﻴﺅ% 21ﻏﺜﻴﺎﻥ % 61(ﺏ)ﺍﻟﻤﺠﻤﻭﻋﺔ  ?
  .ﺘﻘﻴﺅ% 44ﻏﺜﻴﺎﻥ % 67( ﺝ)ﺍﻟﻤﺠﻤﻭﻋﺔ  ?
ﻤﻠﺠﻡ ﻟﻪ ﺩﻭﺭ ﻓﻌﺎل ﻓﻲ ﺨﻔﺽ ﻨﺴـﺒﺔ ﺍﻟﻐﺜﻴـﺎﻥ  01ﻋﻠﻴﻪ ﻓﺎﻥ ﻋﻘﺎﺭ ﺍﻟﺩﻴﻜﺴﺎﻤﻴﺜﺎﺯﻭﻥ 
 0ﻨﻪ ﻴﺘﺴﺎﻭﻯ ﻤﻌﻪﺈﻤﺎ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﺘﻘﻴﺅ ﻓﺃﻤﻠﺠﻡ   6ﺒﺎﻟﻤﻘﺎﺭﻨﺔ ﻤﻊ 
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INTRODUCTION 
 
Postoperative nausea and vomiting (PONV) typically 
occurs in 20 to 30% of surgical cases, with 
considerable variation in frequency reported between 
studies (range 8 to 92%)(1). PONV is generally 
considered a transient, unpleasant event carrying little 
long-term morbidity; however, aspiration of emesis, 
gastric bleeding, and wound hematomas may occur 
with protracted vigorous retching or vomiting. 
Troublesome PONV can prolong recovery room stay 
and hospitalization, and is one of the most common 
causes of hospital admission following ambulatory 
surgery(2). 
Antiemetics may be administered preoperatively or 
intra-operatively to prevent PONV. The latter approach 
(i.e. the “rescue” strategy) is satisfactory for patients 
undergoing surgical procedures, which allow frequency 
of PONV, and for situations where PONV is generally 
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mild or self-limiting. In patients undergoing highly 
emetogenic surgical procedures, it is not uncommon 
for both prophylactic and rescue antiemetics to be used 
in the same patient during the preoperative period(3). 
All preoperative antiemetics appear to have similar 
efficacy in both the prophylaxis and treatment of 
PONV, and carry acceptable side effects profiles.  
Antiemetic drugs available to treat or prevent PONV 
include phenothiazines (chlorpromazine, 
prochlorperazine, and promethazine); antihistamines 
(hydroxyzine and diaphenhydramine); anticholinergics 
(atropine, glycopyrrolate, and scopolamine), 
benzamides (metoclopramide, trimethobenzamide, and 
domeperidone); butyrophenones (droperidol and 
haloperidol); and serotonin (5-HT3) antagonists 
(ondansetron and granisetron(1). droperidol 
metoclopramide and prochlorperazine are the best 
studied, while ondansetron has captured considerable 
recent attention. 
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PONV is influenced by many variables, including 
patient related factors, surgical techniques, type of 
surgery, anesthetic agents employed, and postoperative 
factors(1). Patient related factors, that may lead to a 
higher likelihood of PONV include pediatric age 
group, female gender, obesity, preoperative anxiety, a 
history of severe motions sickness, and presence of an 
underlying disease resulting in delayed gastric 
emptying(1). A prior history of PONV under similar 
anesthetic surgical setting may double the likelihood of 
vomiting following subsequent surgery(4). The type of 
surgery is an important variable. PONV occurs 
frequently in gynecologic laproscopy (50to90%), and 
in strabismus surgery (60-90%). Other surgeries 
associated with frequent PONV  include nose and 
middle ear surgery (30%), head and neck surgery (21 
to 63%), and intra-abdomenal surgery (up to 70%)(5). 
Prolonged duration of surgery and anaesthesia also 
leads to more frequent PONV(6). Postoperative factors 
that may increase the incidence of PONV include pain, 
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dizziness, ambulation, early oral intake, and aggressive 
use of postoperative opiate analgesics(7). Anaesthetic 
techniques using primarily opiates (fantanyl, 
sufentanil, or alfentanil) may increase the incidence of 
PONV tow-to-five folds versus standard inhalation 
techniques(8). Short acting barbiturates, etomidate, 
ketamine, and reversal of neuromuscular blockade may 
increase emetic risks, while midazolam and propofol 
have little influence or may decrease the risk of 
PONV(1). 
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LITERATURE REVIEW 
 
Post-operative nausea and vomiting (PONV) complicates 
the lives of both patients and health care providers. The 
incidence of PONV varies between 20% and 30% 
depending on risk factors for PONV(1). It can be especially 
troublesome in day surgery. At the very least the patient 
experience discomfort, but persistent symptoms causing a 
delay in returning to normal activities for greater than one 
day has been reported(9). Nausea and vomiting may delay 
discharge from the recovery room tying up human and 
material resources(10). and if it is severe enough, may 
require admission to the hospital. For the day surgery 
patients, dependant family members, this can represent 
more than an inconvenience. Although routine prophylaxis 
would seem appropriate, the choice of antiemetic agents is 
wide, and some are too expensive to be cost-effective for 
routine use. 
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This review will examine the physiology of nausea and 
vomiting (n/v), risk factors for PONV and pharmacology 
of Dexamethasone. 
Physiology of nausea and vomiting: 
Nausea: 
Nausea is the uncomfortable sensation of an impending 
episode of vomiting. It is often associated with prodromal 
symptoms such as salivation, swallowing, pallor and 
tachycardia(1). 
It is the conscious recognition of sub conscious excitation 
in an area of the medulla closely associated with or part of 
the vomiting center, and it can be caused by (a) irritative 
impulses coming from the gastrointestinal tract, (b) 
impulses that originate in the lower brain associated with 
motion sickness, or (c) impulses from the cerebral cortex 
to initiate vomiting. 
Vomiting occasionally occurs without the prodromal 
sensation of nausea indicating that only certain portions of 
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the vomiting center are associated with the sensation of 
nausea(11). 
Vomiting: 
Vomiting is a complicated process, mediated by a central 
coordinating “vomiting center” thought to reside in the 
brainstem (close to the tractus solitarius), in the area called 
the parvicellular Reticular formation, or the Emetic Center 
(E.C)(12), it receives inputs from the pharynx, G.I tract, 
mediastinum, higher cortical centers (e.g. the visual, 
gustatory, olfactory and vestibular centers), and the 
Chemoreceptor Trigger Zone (CTZ). The chemoreceptor 
trigger zone is located within the brainstem, in the area 
postrema. Because the blood brain barrier does not protect 
the CTZ, it is exposed to blood borne substances (toxins) 
and relays this information to the EC. CTZ activity is 
modified by a variety of receptors including 
dopaminergic, histaminic, muscarinic and serotonergic. 
Most anti-emetic, drugs have antagonist activity at one or 
more of these receptors. The EC receive this input, and 
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initiates the vomiting sequence in another complex 
interplay of various systems(1,12).  
The “vomiting center” in the reticular formation of 
medulla really consist of various scattered groups of 
neurons in this region that control the different 
components of the vomiting act(11).  
Irritation of the mucosa of the upper gastrointestinal tract 
causes vomiting. Impulses are relayed from the mucosa to 
the medulla over visceral afferent pathways in the 
sympathetic nerves and vagi. Afferent from the vestibular 
nuclei mediate the nausea and vomiting of motion 
sickness. Other afferents presumably reach the vomiting 
control areas from the diencephalons and limbic system, 
because emetic responses to emotionally charged stimuli 
also occur. Thus, we speak about “nauseating smells” and 
sickening sights” (11).  
Chemoreceptor cells in the medulla initiate vomiting when 
they are stimulated by certain circulating chemical agents. 
The CTZ in which these cells are located is in the area 
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postrema, a V-shaped band of tissue on the lateral walls of 
the fourth ventricle near the obex(11).  
This structure is one of the circumventricular organs and is 
more permeable to many substances than the underlying 
medulla. Lesions of the area postrema have little effect on 
the vomiting response to gastrointestinal irritation or 
motion sickness but abolish the vomiting that follows 
injection of apomorphine and number of other emetic 
drugs. Such lesions also decrease vomiting in uremia and 
radiation sickness, both of which may be associated with 
endogenous production of circulating emetic 
substances(12).  
There are 5.HT3 receptors in the small intestine, and 
serotonin (5-HT) released from enterochromaffin cells 
appears to initiate impulses in afferent that trigger 
vomiting. In addition, there are dopamine D2 receptors and 
5-HT3 receptors in the area postrema and adjacent nucleus 
of the solitary tract. 5-HT3 antagonists such as 
ondansetron and D2 antagonists such as chlorpromazine 
and haloperidol are effective antiemetic agents. 
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Corticosteroids, cannabinoids, and benzodiazepines, alone 
or in combination with 5-HT3 and D2 antagonists are also 
useful in treatment of the vomiting produced by 
chemotherapy. The mechanisms of action of corticosteroid 
and cannabinoids are unknown where as the 
benzodiazepines probably reduce the anxiety associated 
with chemotherapy(13). 
Risk factors for PONV: 
Certain risk factors are unavoidable, such as those caused 
by the procedure and those associated with aparticular 
patient. Since these cannot be modified, when they are 
present, diligent prophylaxis should be pursued. The 
choice of anaesthetic is one factor that the anestheisologist 
has control over. These factors can be divided into patient, 
anaesthetic, surgical and post-operative factors (14). 
Patient factors : 
* Age :  
The incidence of vomiting is higher in pediatric patients as 
compared to adults (peak between 11-14) (15).  
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* Gender :  
Adult females have a higher incidence of PONV than 
adult males. This predisposition has been attributed to 
fluctuation in female sex hormone (estrogen) 
concentration during the menstrual cycle. The risk of 
PONV has been reported as increased four fold during 
laproscopy in the first eight days of the menstrual cycle(16).  
* Fasting status:  
Full stomach. 
Gastroparesis (e.g. diabetes, chronic cholecystitis, bowel 
obstruction and some neuromuscular disorders. 
As noted by John Snow over 150 years ago, food in the 
stomach stimulates abdominal vagal afferents both by its 
chemical composition and by volume which, in 
combination with the central effects of anesthetics may 
provide sufficient emetic drive(17).  
* Anxiety : 
Psychological stress induces the secretion of endocrine 
hormones including prolactin and catecholamines, which 
may be acontributing factor for emesis(6).  
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* Body habitus : 
The risk of PONV increased in obese patients (defined as 
body mass index greater than 30 Kg/m2). Possible 
explanations include larger residual gastric volume, higher 
incidence of oesophageal reflux, and adipose tissue may 
act as a reservoir for inhaled anesthetic agents that 
continue to enter the vascular space even after 
administration has been discontinued(1).  
Inspite of these explanations, however, no direct 
relationship has been found between body mass and the 
incidence of PONV(18).  
* History of previous PONV or motion sickness : 
Patients with a history of vomiting after previous surgery 
or history of motion sickness are more susceptible to 
PONV than those without a history(1,4).  
These patients may have a well developed reflex arc 
sensitized by previous emetic stimuli, that predisposes 
them to vomiting (6). 
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Anesthetic factors: 
Premedication: 
Administration of opioids by any route, intravenous, 
intramuscular, oral, nasal or transmucosal has been 
observed to increase PONV(1).  
The emetic effects of opioids are belived to be via an 
action on opioid receptors (probably mu) present in the 
area postrema.(12) Morphine enhances the release of 5-HT 
from the small intestine enterochromaffin cells. The 
release of 5-HT has been implicated in the mechanism of 
emesis induced by anticancer therapy(12,19). Opiods in 
higher doses can also depress the CTZ stimulating effect, 
thereby reducing the occurrence of nausea and vomiting. 
However, avoidance of opioids in the postoperative period 
may contribute to PONV secondary to visceral pain(8).  
The addition of anticholinergic medications (i.e. atropine 
and hyoscine) to opioid premedication has been shown to 
decrease postoperative emesis(20). The anti-emetic 
properties of the anticholinergic agents result from a 
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central rather than a peripheral mode of action. This 
supposition is supported by the finding that glycopyrolate 
(quaternary ammonium compound unable to cross the 
blood brain barrier), when used as an alternative to 
hyoscine has no antiemetic property(21).  
Intravenous induction agents: 
Ketamine and etomidate are two intravenous induction 
agents associated with a high incidence of nausea and 
vomiting. The emetic effects of ketamine may be 
secondary to the release of endogenous catecholamines. 
Propofol is an intravenous induction agent associated with 
a lower incidence of PONV as compared to other agents. 
This effect of propofol has been confirmed in various 
retrospective and prospective studies. The low incidence 
of PONV and rapid emergence from anaesthesia are the 
reason for the great popularity of propofol in outpatient 
surgery(1).  
Nitrous oxide: 
The issue that nitrous oxide (N2O) may increase the 
incidence of nausea and vomiting has been a controversial 
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topic for years. However, the results of meta-analyses of 
twenty-seven studies showed that N2O does increase the 
incidence of PONV as compared with alternative 
anaesthetic techniques(22). 
Volatile anesthetics : 
It has been suggested that subanesthetic dose of halothane 
may have an anti-emetic effect. However, data from 
outcome studies suggest that there is no significant 
difference between halothane, isoflurane and enflurane 
with respect to the incidence of postoperative emesis(1).  
Muscle relaxants: 
Muscle relaxants per se are not considered to have an 
effect on the incidence of PONV, however, antagonism of 
residual neuromuscular block with anticholinesterases, 
result in increased postoperative emesis. The muscarinic 
effects of these agents increase gastrointestinal motility, 
which may contribute to increased incidence of PONV(23).  
Regional anaesthesia: 
The incidence of PONV is lower after regional than after 
general anesthesia. However, this difference narrows if 
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parenteral opioids are administered intra or post 
operatively. The incidence of emesis after central 
neuroaxial blocks (spinal, epidural) is greater than after 
peripheral nerve blocks because of the associated 
sympathetic nervous system blockade. Hypoxemia at the 
vomiting center and vagal stimulation have been 
suggested as stimulants to emesis and administration of 
100% oxygen and or intravenous administration of 
atropine was noted to decrease the incidence of PONV(1).  
Surgical factors: 
Type of surgery: 
In children certain types of procedures including 
strabismus surgery, orchidopexy, tonsillectomy, middle 
ear surgery and otoplasty are associated with a higher 
incidence of PONV(1). Intra-abdominal procedures are 
more emesis producing than extra-abdominal operations 
as are laproscopic procedures(6).  
Duration of surgery : 
The incidence and severity of PONV increases with 
greater duration of surgery. During longer operations the 
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level of stress hormone may be elevated and the patient 
may receive a larger number of potentially emetic 
anesthetic drugs or surgical stimulation may be more 
protracted and intense(7).  
Post-operative factors: 
? Pain (especially pelvic). 
? Dizziness (dehydration, hypotension). 
? Motion (sitting up too early). 
? Oral intake (early). 
? Narcotics (post-operative). 
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Dexamethasone: 
Description: 
Dexamethasone and its derivatives, dexamethasone 
sodium phosphate and dexamethasone acetate, are 
synthetic glucocorticoids used as anti-inflammatory or 
immunosuppressive agents. 
Dexamethasone has non or very little mineralocorticoid 
activity and is therefore not used in the management of 
adrenal insufficiency. Dexamethasone is usually selected 
for management of cerebral edema because of its superior 
ability to penetrate the CNS. Dexamethasone is one of the 
longest acting corticosteroids used in clinical medicine. It 
is available in oral, parenteral, topical, ophthalmic and 
inhalation dosage forms. The FDA approved 
dexamethasone in 1958. 
Mechanism of Action: 
Glucocorticoids are naturally hormones that prevent or 
suppress inflammation and immune responses when 
administered at pharmacological doses. At molecular 
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level, unbound glucocorticoids readily cross cell 
membranes and bind with high affinity to specific 
cytoplasmic receptors. This binding induces a response by 
modifying transcription and ultimately, protein synthesis 
to achieve the steroids intended action. Such actions can 
include: Inhibition of leukocytes infiltration at the site of 
inflammation, interference in the function of mediators of 
inflammatory response, and suppression of humoral 
immune responses. Some of the net effects include 
reduction in edema or scar tissue and general suppression 
in immune response. The degree of clinical effect is 
normally related to the dose administered. Daily, high-
dose therapy is generally recommended if serious organ 
involvement, whereas every-other-day therapy may be 
acceptable for less sever, chronic conditions. Likewise, the 
numerous adverse effects related to corticosteroids use 
usually depend on the dose administered and the duration 
of therapy. 
Orally, inhaled corticosteroid hormones are believed to 
reduce the immediate and late-phase allergic responses 
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associated with chronic bronchial asthma. Proposed 
mechanisms of action include decreased IgE synthesis , 
increased number of B-adrenergic receptors on leukocytes 
and decreased arachidonic acid metabolism, which 
decreases the amount of prostaglandin and leukotrienes 
released. Chronic bronchial asthma is associated with 
increased peribronchial edema and mucus secretions, 
which can be decreased with corticosteroid therapy. 
During an immediate allergic reaction, allergens bridge 
the IgE antibodies on the surface of mast cells, which 
triggers these cells to release chemo tactic substances. 
Mast cell influx and activation, therefore, is partially 
responsible for the inflammation and hyperirritability of 
the oral mucosa in asthmatic patients. This inflammation 
can be retarded by administration of adrenocorticoids. 
Pharmacokinetics: 
Dexamethasone is rapidly absorbed following an oral 
dose. Peak effects following oral administration occur 
with 1-2 hours. The onset and duration of action of 
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Dexamethasone injection ranges from 2days to 3 weeks 
and is dependent on whether the drug is administered by 
intra-articular or intra-muscular injection and by the extent 
of the local blood supply. Systemic bioavailability of 
dexamethasone after topical application depends on the 
state of the skin at the application site. 
Absorption of topical preparations is increased in areas of 
skin damage, inflammation and occlusion, or where the 
stratum corneum is thin such as the eyelids, genitalia, and 
face. There may be a small extent of systemic absorption 
of the topical solutions, especially via the oral mucosa. 
Following ophthalmic administration, dexamethasone is 
absorbed through the aqueous humor, with only minimal 
systemic absorption occurring. The systemic absorption of 
the inhalant preparation of dexamethasone ranges from 
30-50% of an orally inhaled dose. Although the onset of 
action typically occurs within a few days, it can take as 
long as seven days. 
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Topical preparations distribute throughout the area of 
application; ophthalmic preparations distribute into the 
local tissues; and orally administered inhalant doses 
distribute throughout the mouth and throat. The 
distribution kinetics of an intranasal dose of 
dexamethasone is unknown. Circulating drug binds 
weakly to plasma proteins, with only the unbound portion 
of a dose being active. Systemic dexamethasone is quickly 
distributed into the kidneys, intestines, skin, liver and 
muscle. 
Corticosteroids distribute in to breast milk and cross the 
placenta. 
Topical preparations of dexamethasone are metabolized in 
the skin, ophthalmic doses are metabolized locally, and 
the liver to inactive metabolites metabolizes systemic 
dexamethasone. These inactive metabolites, as well as a 
small portion of unchanged drug, are excreted in the urine. 
The biological half-life of dexamethasone is 36-54 hours. 
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Indications: 
For primary or secondary adrenocortical insufficiency,  
(hydrocortisone or cortisone is the first choice) ; 
congenital adrenal hyperplasia, non suppurative 
thyroiditis, hypercalcemia associated with cancer; for 
adjunctive therapy in the treatment of rheumatic disorders, 
e.g., rheumatoid arthritis, juvenile arthritis, psoriatic 
arthritis, ankylosing spondylitis, acute and sub acute 
bursitis, acute gouty arthritis, for maintenance therapy in 
selected cases of systemic lupus erythematosus, and acute 
rheumatic carditis for the treatment of pemphigus, 
dermatitis, psoriasis, allergic. 
Conjunctivitis, keratitis , allergic corneal ulcers, iritis optic 
neuritis, sympathetic ophthalmia, aspiration pneumonitis, 
idiopathic thrombocytopenic purpurea, thrombocytopenia, 
congenital hypoplastic anemia; for palliative management 
of leukemias and lymphomas in adult and acute leukemias 
of childhood; for edematous states; for critical periods of 
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ulcerative colitis and regional enteritis, tuberculous 
meningitis; inflammation and immunosuppression. 
Dosage : 
Must be individualized and is very variable depending on 
the nature and severity of the disease, and on the patients 
response. If therapy is continued for more than a few days, 
withdrawal must be gradual. 
# For hypothalamic pituitary adrenal (HPA) suppression 
diagnosis: 
1- Test for Cushing’s syndrome: 
Oral dosage (dexamethasone): 
Adults : 0.5mg PO every 6 hours for 48 hours. 24 hours 
urine collections are made for determination of 
17–hydroxycorticosteroid excretion. 
Alternatively. 1mg PO at 11:00 Pm. Morning 
plasma cortisol determination is drowns at 8:00 
am. 
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2- Test to distinguish Cushing’s syndrome secondary to 
pituitary ACTH excess from Cushing’s syndrome due 
to other causes : 
Oral dosage (dexamethasone). 
Adult : 2mg PO every 6 hours for 48 hours. 24 hour urine 
collections are made for determination of 17–
hydroxycorticosteroid excretion. 
3- Use of test to confirm diagnosis of melancholic 
depression: 
oral dosage (dexamethasone). 
Adults : 1mg PO at 11:00 pm  plasma cortisol 
determination is drawn the following day at 
4:00pm and 11:00pm. 
# For the treatment of anaphylactic shock : 
Intravenous dosage (dexamethasone sodium phosphate) . 
Adults : 1-6mg/Kg IV or 40mg IV every 4-6 hours  while 
shock persists. Alternatively, 20mg IV injection 
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followed by an IV infusion of 3mg/Kg IV 
infusion over 24 hours. 
# For treatment of cerebral oedema: 
Intravenous or intramuscular dosage (dexamethasone 
sodium phosphate. 
Adults : 10mg IV injection, followed by 4mg IM every 6 
hours, until symptoms subside. A response 
should be seen within 12-24 hours, and a 
gradual dose reduction begun after 2-4 days, 
reducing over another 5-7 days. Replace IM 
dexamethasone with oral as soon as possible. 
Where maintenance therapy is needed, 2mg IM 
or IV can be given 2-8 times/day to reduce 
intracranial pressure. 
Children : Initially, 0.5-1mg/Kg IV, then 0,25 – 0,5 
mg/Kg/day in divided doses. Doses should be 
tapered if used for more than 14 days. 
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# For treatment of acute anaphylaxis : 
Intramuscular dosage (dexamethasone sodium phosphate), 
oral dosage (dexamethasone) : 
Adults : 4-8mg IM on day one. Then change to oral 
therapy, 3mg PO, given in 2 divided doses on 
the second day and third day; 1,5mg PO, given 
in 2 divided doses on day 4; 0,75mg PO on 
days 5 and 6, then discontinue drug. 
# For prophylaxis of respiratory distress syndrome in 
premature infants : 
intramuscular dosage (dexamethasone sodium phosphate): 
Expectant mother . 4mg IM 3times/day for 2 days prior to 
delivery. 
# For treatment of nausea/vomiting associated with cancer 
chemotherapy : 
Intravenous dosage (dexamethasone sodium phosphate) : 
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Adults : 10-20mg IV before administration of 
chemotherapy. Additional lower doses may 
be given for 24-72 hours, as needed. 
# For the reduction of edema and inflammation associated 
with selected cases of otitis externa : 
Otic dosage (dexamethasone sodium phosphate) : 
Adults : Instill 3 or 4 drops into the aural canal 2 or 3 
times a day. 
Contraindications/ Precautions: 
Complications including cleft palate, still birth and 
premature abortion, have been reported when 
corticosteroids were administered during pregnancy. 
Babies born to women receiving large doses of 
corticosteroids during pregnancy should be monitored for 
signs of adrenal insufficiency, corticosteroids distribute 
into breast milk, and the manufacturer states that women 
receiving pharmacological dosages of corticosteroids 
should not breast feed. 
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Children receiving dexamethasone inhalant therapy should 
be monitored closely for possible adverse effects on 
growth patterns. The safety and efficacy of the drug have 
not been determined for children under 6 years of age. 
Drug interaction: 
Hepatic microsomal enzyme inducers, including 
barbiturates, phenytoin and rifampicin, can increase the 
metabolism of glucocorticords. 
Corticosteroid can increase the risk of GI ulceration 
secondary to nonsteroidal anti inflammatory drugs. 
Aspirin should be used with caution. Serum salcieylate 
levels can increase when corticosteroid therapy is 
discontinued. 
Glucocorticorids interact with cholinesterase inhibitors 
including ambenonium, neostagmine and pyridostigmine, 
causing sever muscle weakness in patients with 
myasthenia gravis who receive these drugs concomitantly. 
In general, toxoids and vaccines should not be 
administered to patients receiving corticosteroids. 
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Corticosteroid therapy may rarely increase blood 
coagulability, corticosteroid have been associated with 
gastrointestinal bleeding. Corticosteroids can cause 
hyperglycemia, requiring the readjustment of oral 
hypoglycemics or insulin in diabetc patients. 
Patient receiving digoxin and corticosteroid concomitantly 
are at an increased risk for developing arrhythmias or 
digitalis toxicity due to corticosteroid induced 
hypokalemia. 
Adverse reactions: 
Abdominal pain, acne, amenorrhea, anorexia, anxiety, 
arthralgias, arthropathy, a vascular necrosis, bone 
fractures, cataracts, constipation, contact dermatitis, 
Cushing’s syndrome, depression, diarrhea, hoarseness, 
hyperglycemia, hypertention, hypokalemia, hypotension, 
hypothalamic –pituitary- adrenal (HPA) suppression, 
impaired wound healing, increased intraocular pressure, 
infection, insomnia, lethargy and miliaria. 
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Potential side effects: 
Mild : 
Dexamethasone can cause increased appetite, upset 
stomach, nervousness or restlessness, or trouble sleeping. 
When applied to the skin, ears, eyes or nose, it can cause 
burring, dryness, irritation or redness these side effects are 
usually mild and may go away as your body adjusts to the 
medication. 
Serious/Limiting : 
This medication can lower resistance to infection. Notify 
your doctor if you experience sore throat, fever, sneezing, 
cough or other sings of infection or if exposed to any one 
with measles, chickenpox or recent polio immunization. 
When given by injection, dexamethasone can cause pain, 
redness, swelling, and sings of allergy or scarring at the 
injection site. It also can cause sudden blindness when 
injected into the head or neck area. 
If you stop taking this medication, your body may need 
time to readjust. May experience : stomach or back pain, 
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dizziness, fainting , fever, loss of appetite, muscle or joint 
pain, nausea, a return of disease symptoms shortness of 
breath, unexplained headaches, unusual tiredness or 
weakness,  vomiting or weight loss. 
Prevention and treatment of PONV: 
Management of PONV should be focused on prevention 
rather than treatment as the latter provides better efficacy 
than rescue. 
Although routine anti-emetic prophylaxis is unjustified, 
patients at high risk for PONV should receive special 
consideration with respect to the implementation of an 
appropriate prophylactic regimen(24). 
Prophylactic anti-emetics can reduce, but do not 
completely eliminate, PONV in ‘high risk’ emetogenic 
circumstances. As early at 1960, Keats discouraged 
routine anti-emetic prophylaxis in anesthesia(25).  
Adriano et.al, noted that only 3,5% of patients in their 
series had persistent vomiting that required treatment, and 
that a large fraction of PONV occurred at emergence from 
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anaesthesia and did not recur. Prophylactic anti-emetics 
were regarded as unjustified. Although the morbidity 
associated with nausea is probably very low, patient 
discomfort is an important factor, and should not be 
ignored or considered unavoidable(26).  
Splinter, William are noted that 50µg/kg ondansetron plus. 
150µg/kg dexamethasone more effective decreases the 
incidence and severity of vomiting than does150µg/kg 
ondansetron(27).  
Also in arandomized double-blinded placebo controlled 
study Wang J.J and Liu found that dexamethasone 10mg 
significantly decreases the incidence of postoperative 
nausea and vomiting in women undergoing ambulatory 
laparascopic surgery(28).  
Wang J.J and his colleagues they are found prophylactic 
dexamethasone 8mg significantly reduced the incidence of 
nausea and vomiting after laproscopic cholecystectomy(29). 
The compination of 4mg ondansetron and 8mg 
dexamethase reduced the incidence of emetic episodes 
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compared with ondansetron alone. And if caused better 
control of delayed nausea and vomiting rather than early 
PONV. 
Fujii, Yoshitaka are noted that, an administration of 
granisetron 20µg/kg plus dexamethasone 8mg IV is more 
effective in the prophylaxis of postoperative nausea and 
vomiting after recovery from anesthesia than that of 
granisetron 20µg/kg alone. 
The prophylactic administration of either IV 
dexamethasone 10mg or IV droperidol 1.25mg 
significantly reduced the incidence of PONV in patients 
undergoing thyroidectomy. However, patient who 
received droperidol reported a higher intensity of sore 
throat and amore frequent incidence of restlessness than 
those receiving dexamethasone. They suggest that IV 
dexamethasone 10mg is a useful treatment for preventing 
PONV in women under going thyroidectomy. 
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OBJECTIVES 
 
A low cost anti-emetic agent with few side effects would 
be of benefit to anaesthetists and their patients. 
The aim of this study: 
• To evaluate the prophylactic anti-emetic effect of 
intravenous dexamethasone using two doses 6mg 
and 10mg compared to a placebo. 
• To study and correlate the risk factors of 
postoperative nausea and vomiting. 
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PATIENTS AND METHODS 
 
This prospective study was carried out in Khartoum 
Teaching Hospital and Soba University Hospital from 
January to December 2003. 
One hundred fifty patients were included in the study, 
adults ASA I or II scheduled for elective operations, 
informed medical consent and local ethics committee was 
verbally obtained from the patients. 
On arrival in the operating room, routine monitoring 
devices were placed and baseline blood pressure, heart 
rate and pulse oximetry values were recorded. Patients 
were then randomly assigned to one of three groups (n=50 
each) with help of another registrar to prepare it in syringe 
2ml coded A, B and C. (the researcher being blinded to the 
code). At the time of induction one group of patients 
received A intravenously, the second group received B 
and the third one received C. 
 37
The anaesthetic regimen was standardized for all patients, 
0.5-1mg of atropine immediately before induction, 
thiopentone 5mg/Kg, suxamethonium 1.5mg/Kg were 
administered and endotracheal tube was inserted and the 
patients lungs were ventilated manually, anaesthesia was 
maintained with 33% oxygen in nitrous oxide. After 
recovery from suxacmethonim 0.1mg/Kg of pancuronim 
was administered. During surgery another two reading of 
vital signs were taken. 
At the cessation of the surgery, atropine 0.5-1mg and 
neostagmine 0.05mg/Kg were administered intravenously 
to reverse the neuromuscular block, and the tracheal tube 
was removed. 
After surgery the patients were transported to the recovery 
room during their stay, blood pressure, heart rate and 
respiratory rate were monitored every 15 minutes, then the 
patients were observed for 24 hours and questioned 
directly for the first 4 hrs half an hour for the occurrence 
of nausea vomiting or pain. 
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Clinical out come data were assessed during three periods 
after surgery (0-4 hrs), (5-12hrs) up to 24hrs. The 
assessments were made at the end of each time interval 
and the score during each interval for each symptom was 
recorded. The severity of nausea was assessed by the 
patients using standard four point ordinal scales (non-
mild- moderate and severe) the single worst score for 
nausea from any of the three time periods before discharge 
were used for analysis. 
The major parameters measured were the incidence of 
vomiting before discharge, the need for rescue anti-emetic 
and the frequency of a complete response (defined as the 
absence of any nausea and vomiting during the whole 
study period). Patients were discharged from the day case 
unit when they were able to take oral fluids and walk 
independently. 
The interview results were transferred into a master sheet, 
which was entered into a computer-using database III 
package statistical programmer for social sciences. 
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Computer package (SPSS-Pc) was used for data analysis. 
Simple frequency distribution and relative frequency were 
used for tabulation. 
Parametric data were analyzed with the unpaired t test. 
Non-parametric data were analyzed using the Mann 
Whitney U test. Categorical data were analyzed with the 
chi-squared test. A P value less than 0.05 were considered 
significant. 
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RESULT 
 
This is a prospective, comparative double blind study, 
done among one hundred fifty patients, in Soba University 
Hospital and Khartoum Teaching Hospital.  The risk 
factors of PONV were studied, and the anti-emetic effect 
of dexamethasone in different doses were compared with 
placebo, in this study, group (A) referred to 
dexamethasone 6mg, group (B) dexamethasone 10mg and 
group (C) normal saline, each of them in a dose of 2ml. 
In this study most of patients were in the age group of 31-
45 (37%) table (1). 
It is clearly seen that the females gender predominates and 
constituted (61%) of the study while males constituted of 
(39%) fig. (1). 
Table (2) shows that gynecological problems were the 
commonest, 54 patients (36%) followed by abdominal, 
orthopedics, plastic, ENT and others. 
Table (3) shows the distribution according to the type of 
operation and correlation of incidence of PONV. 
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Laproscopic and intra-abdominal surgeries had the highest 
frequency and incidence of PONV. 
Table (4) shows the relation between the age of the 
patients and the drug code it was seen that most of patients 
under the study were between the age group of 15 and 30 
years. 
In relation between sex and drug code it is clear that 
female predominate in group (A) 38 pts. (41.3%) while the 
male was the least at the same group, 12 pts. (20,7%). 
Table 5. 
Table (6) shows relation between incidence and severity 
of nausea. 
In relation between the drug code and incidence of nausea 
it’s clear that nausea occurred less in group (B) 8 pts. 
(16%) table (7). 
Postoperative vomiting occurred in 34 patient (22,7%) 
fig.(2). 
Concerning the relation between incidence of 
postoperative vomiting and drug code among patients in 
each group table (8). 
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It is clearly seen that the incidence of postoperative pain in 
this study occurred in 42 patients (28%) fig. (3). 
Among the study groups; 42 patients experienced pain, 2 
of that only, had vomiting as well table (9). 
Fig. (4) shows the incidence of analgesics requirement 
only 54 patient (36%) need postoperative analgesia. 
Thirty four patients developed vomiting; 24 from them 
received postoperative analgesics Fig. (5). 
In relation between the drug code and complete response, 
the best result obtained in group (B). 42 patient (84%). 
Table (10). 
Table (11) shows relation between type of operation and 
complete response. 
No discernible side effects accompanying dexamethasone 
usage were observed. 
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DISCUSSION 
 
This research studied the effect of intravenous 
dexamethasone, in two different doses, given with 
induction to prevent nausea and vomiting. 
Females were affected more than males. The ratio was 
92:58 (1,6:1) and this is in agreement with Beattie 
(1991)(16), who correlated this high incidence of PONV in 
females to fluctuation in female sex hormones level during 
menstrual cycle. 
There was no significant difference among groups 
regarding weight and duration of surgery. 
Concerning the type of operation it was clearly seen that, 
there were relations between the type of operation and the 
incidence of PONV, where abdominal and laproscopic 
surgeries had concern the highest incidence of PONV 
[(68) patients (45%) and 28 patients (19%) respectively]. 
This is in agreement with Malins (1994)(5) who related this 
event to irritation of the gas used in this type of operation. 
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Regarding the relation between incidence of nausea per 
hour and its severity, it was found that the severity of 
nausea decreased gradually with time, in 82% of cases 
during 12-24 hours postoperatively; this was in agreement 
with the study done by Adriano (1976) and Kopur 
(1991)(26). 
In patients who received dexamethasone 10mg it was seen 
that nausea occurred only in 8 patients (16%), this is in 
agreement with Wang and Liu (1999)(28). 
The two groups of patients who received dexamethasone 
in two different doses had lower incidence of PONV, 
compared with the control group, this result agreed with 
that of Wang and Liu who reported that dexamethasne 
significantly decreases the incidence of PONV. 
In relation between doses of dexamethasone and complete 
response, the best result was obtained in patients who 
received dexamethasone 10mg 42 patients (84%). 
Patients who underwent orthopedics surgeries showed the 
best response to dexamethasone as postoperative 
antiemitic (72%), while the least response was seen in 
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those who underwent laproscopic surgeries (43%) this 
may be related to the site of surgery which is affecting the 
upper part of the GIT. 
ENT surgeries showed good response to dexamethasone 
as postoperative antiemetic (70%) inspite of the high 
incidence of PONV in this group because of stimulation of 
the pharyngeal afferent nerves and presence of blood in 
the GIT. 
It was found that postoperative pain causes vomiting. This 
was demonstrated in 24 patients who received analgesia 
for pain, after which the vomiting stopped. Belleville 
1960(7) related this result to the direct effect of pain on the 
vomiting center. 
Most of the studies were done using single dose of 
dexamethasone, in this study two doses were used 6mg 
and 10mg and it was found that the 10mg dose gave 
superior results to the 6mg dose especially regarding the 
nausea. 
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CONCLUSION 
 
1. Dexamethasone 10mg was found to be very 
effective in reducing the incidence of PONV. 
2. Dexamethasone 6mg was effective in reducing 
postoperative vomiting in a similar way to the 10 
mg dexamethasone, but was less effective than the 
10mg dexamethasone in reducing postoperative 
nausea. 
3. It was found that the following factors increase the 
incidence of post operative nausea and vomiting : 
Female gender, history of severe motion sickness, 
prior history of PONV and the type of surgery is 
an important variable. 
4. Dexamethasone more advantageous in term of 
cost, absence of side effects and sedation. 
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RECOMMENDATION 
 
1. The dose of 10mg dexamethasone is 
recommended to be used with induction of 
anesthesia as prophylaxis of PONV especially in 
high risk patients. 
2. To use the 6mg dose in patient who has no risk 
factors. 
3. More studies on different doses of dexamethasone. 
4. More studies in high risk factors. 
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Table 1 
 
Age distribution among patient under study 
 
% Frequency  Age group(years) 
33 50 15-30 
37 56 31-45 
20 30 46-60 
10 14 61-75 
100 150 Total 
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Table  2 
                
Distribution according to  diagnosis 
 
  
Diagnosis Frequency % 
Gynecological 54 36 
Abdominal 38 25 
Fractures 20 13 
Plastic 18 12 
ENT 12 08 
Others 8 06 
Total 150 100 
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Table  3 
Distribution according to  type of operations 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type of surgery Frequency % 
Intra abdomenal 68 45 
Laproscopic 28 19 
Plastic and general 26 17 
Orthopedics 18 12 
ENT 10 7 
Total 150 100 
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Table 4 
Relation between age and drug code 
 
P = 0.003 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age in (years) 
Drug code Total 
A B C 
50 
(33%) 15-30 
 
10 
(20%) 
 
28 
(56%) 
 
12 
(24%) 
31-45 
 
20 
(36%) 
 
14  
(25%) 
 
22 
(89%) 
59  
(37%) 
46-60 
 
14 
(47%) 
 
4 
 (13%) 
 
12 
(40%) 
30 
(20%) 
61-75 
 
6 
(43%) 
 
4 
(29%) 
 
4 
(29%) 
4 
(10%) 
Total 50 50 50 150 
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Table 5 
Relation between sex and drug code 
 
 
Sex 
Drug code 
Total 
A B C 
Male 12 (21%) 
20 
(35%) 
26 
(45%) 
58 
(34%) 
Female 38 (41%) 
30 
(33%) 
24 
(26%) 
92 
(61%) 
Total 50 50 50 150 
 
P = 0.016 
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  Table 6 
 
Relation between incidence and severity of nausea 
 
 
    P = 0.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type of severity 
of nausea 
Incidence in hours 
0-4 5-12 <24 
None 30 (20%) 100 (67%) 122 (81%) 
Mild 76 (51%) 20 (13%) 12 (8%) 
Moderate 18 (12%) 20 (13%) 14 (9%) 
Severe 26 (17%) 10 (7%) 2 (2%) 
Total 150 (100%) 150 (100%) 150 (100%) 
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Table 7 
 
Relation between drug code and incidence of nausea 
 
Total 
Drug code 
Nausea 
C B A 
57 
(38%) 
38 
(76%)
8 
(16%)
11 
(22%) 
Yes 
93 
(62%) 
12 
(24%) 
42 
(84%) 
39 
(88%) 
No 
150 50 50 50 Total 
 
P = 0.016 
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Table 8 
 
Relation between vomiting incidence and drug code 
 
Vomiting 
incidence Drug code Total 
 A B C 
Yes 6 
(18%) 
6 
(18%) 
22 
(64%) 
34 
(23%) 
No 44 
(38%) 
44 
(38%) 
28 
(24%) 
116 
(77%) 
Total 50 50 50 150 
(100%) 
 
P. values 
A = 0.00 
B = 0.00 
C = 0.39 
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Table 9 
 
Relation between incidence of pain and vomiting 
 
Vomiting Pain incidence Total Yes No 
Yes 2 
(6%) 
32 
(94%) 
34 
(23%) 
No 40 
(35%) 
76 
(65,5%) 
116 
(77%) 
Total 42 
(28%) 
108 
(72%) 
150 
(100%) 
 
P = 0.386 
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Table 10 
 
Relation between complete response and drug code 
 
Complete 
response 
Drug code Total A B C 
Yes 34 
(68%) 
42 
(84%) 
17 
(34%) 
93 
No 16 
(32%) 
8 
(16%) 
33 
(66%) 
57 
Total 50 50 50 150 
 
P = 0.007 
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    Table 11 
 
Relation between type of operation and complete response 
(No. PONV at any time) 
 
Type of operation 
Complete response No. 
PONV Total 
Yes No 
Intra-abdominal 46 
(68%)
22 
32%) 
68 
(45%) 
Laprascopic 12 
(43%)
16 
(57%) 
28 
(19%) 
Plastic and general 15 
(58%)
11 
(42%) 
26 
(17%) 
Orthopedics 13 
(72%)
5 
(28%) 
18 
(12%) 
ENT 7 
(70%)
3 
(30%) 
10 
(7%) 
Total 93 57 150 
(100%) 
 
P = 0.00 
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Figure 1 
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Figure 4 
 
Incidence of analgesic requirement 
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Figure (5) 
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ABBREVIATION 
 
PONV   : Post Operative Nausea and Vomiting. 
EC   : Emetic Center. 
CTZ   : Chemoreceptor Trigger Zone. 
IV   : Intravenous. 
IM   : Intramuscular. 
GIT   : Gastro Intestinal Tract. 
ASA   : American Society Anaethesiologest.  
Pt (s)   : Patient(s). 
 
